BlackRock’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $193M | Buy |
|
|||||
|
2025
Q2 | $227M | Buy |
|
|||||
|
2025
Q1 | $223M | Sell |
|
|||||
|
2024
Q4 | $275M | Buy |
|
|||||
|
2024
Q3 | $324M | Buy |
|
|||||
|
2024
Q2 | $230M | Buy |
|
|||||
|
2024
Q1 | $244M | Sell |
|
|||||
|
2023
Q4 | $251M | Buy |
|
|||||
|
2023
Q3 | $181M | Buy |
|
|||||
|
2023
Q2 | $234M | Buy |
|
|||||
|
2023
Q1 | $195M | Buy |
|
|||||
|
2022
Q4 | $201M | Buy |
|
|||||
|
2022
Q3 | $163M | Buy |
|
|||||
|
2022
Q2 | $215M | Buy |
|
|||||
|
2022
Q1 | $250M | Sell |
|
|||||
|
2021
Q4 | $293M | Buy |
|
|||||
|
2021
Q3 | $311M | Sell |
|
|||||
|
2021
Q2 | $333M | Sell |
|
|||||
|
2021
Q1 | $622M | Buy |
|
|||||
|
2020
Q4 | $732M | Buy |
|
|||||
|
2020
Q3 | $395M | Sell |
|
|||||
|
2020
Q2 | $384M | Buy |
|
|||||
|
2020
Q1 | $203M | Sell |
|
|||||
|
2019
Q4 | $202M | Buy |
|
|||||
|
2019
Q3 | $198M | Buy |
|
|||||
|
2019
Q2 | $280M | Sell |
|
|||||
|
2019
Q1 | $329M | Buy |
|
|||||
|
2018
Q4 | $195M | Buy |
|
|||||
|
2018
Q3 | $332M | Sell |
|
|||||
|
2018
Q2 | $337M | Buy |
|
|||||
|
2018
Q1 | $216M | Buy |
|
|||||
|
2017
Q4 | $173M | Sell |
|
|||||
|
2017
Q3 | $200M | Buy |
|
|||||
|
2017
Q2 | $217M | Buy |
|
|||||
|
2017
Q1 | $215M | Buy |
|
|||||
|
2016
Q4 | $218K | Sell |
|
|||||
|
2016
Q3 | $301K | Buy |
|
|||||
|
2016
Q2 | $194K | Buy |
|
|||||
|
2016
Q1 | $159K | Sell |
|
|||||
|
2015
Q4 | $4.2M | Sell |
|
|||||
|
2015
Q3 | $4.08M | Buy |
|
|||||
|
2015
Q2 | $93K | Buy |
|
|||||
|
2015
Q1 | $10K | Hold |
|
|||||
|
2014
Q4 | $7K | Hold |
|
|||||
|
2014
Q3 | $9K | Hold |
|
|||||
|
2014
Q2 | $7K | Sell |
|
|||||
|
2014
Q1 | $531K | Buy |
|